Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17137630 | PROBE HOLDER ILLUMINATION FOR ULTRASOUND IMAGING SYSTEMS | December 2020 | April 2024 | Allow | 39 | 3 | 0 | No | No |
| 17136447 | DIAGNOSTIC ULTRASOUND APPARATUS | December 2020 | June 2024 | Abandon | 41 | 4 | 0 | No | No |
| 17125662 | WEARABLE PORTABLE ULTRASOUND PROBE WITH DUAL ARRAY AND SYSTEM | December 2020 | November 2023 | Allow | 35 | 3 | 0 | No | No |
| 17055784 | DYNAMIC ANGIOGRAPHIC IMAGING | November 2020 | February 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17082028 | LEARNING DEVICE, LEARNING METHOD, AND LEARNED MODEL | October 2020 | January 2024 | Allow | 38 | 3 | 0 | No | No |
| 17071475 | Combination Therapy of Electric Fields and an Additional Treatment for Cancer and Imaging | October 2020 | August 2024 | Allow | 46 | 1 | 0 | No | No |
| 16981822 | TREATMENT OF DEPRESSION | September 2020 | August 2024 | Allow | 47 | 1 | 0 | Yes | No |
| 16979619 | MEDICAL IMAGE PROCESSING DEVICE, TREATMENT SYSTEM, AND STORAGE MEDIUM | September 2020 | May 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 16979216 | WRIST-WATCH BACK CASES, SYSTEMS AND METHODS FOR MEASURING BIOMARKERS | September 2020 | June 2024 | Allow | 45 | 1 | 0 | Yes | No |
| 17008307 | ULTRASOUND REMOTE MONITORING, OPERATING AND TRAINING SYSTEM | August 2020 | March 2024 | Allow | 43 | 6 | 1 | No | No |
| 16994185 | Automatic Ultrasonic Scanning System | August 2020 | January 2024 | Abandon | 41 | 1 | 0 | No | No |
| 16990086 | INFERENCE PROCESS VISUALIZATION SYSTEM FOR MEDICAL SCANS | August 2020 | February 2024 | Allow | 42 | 1 | 0 | No | No |
| 16988438 | Methods and Apparatuses for Central Venous Pressure Measurement Status | August 2020 | June 2024 | Allow | 47 | 1 | 0 | Yes | No |
| 16966613 | METHODS FOR DETECTING POSITIONAL MOVEMENT OF ORTHOPEDIC IMPLANTS | July 2020 | November 2024 | Abandon | 52 | 2 | 0 | No | No |
| 16965755 | DISPLAY WITH FOLDED OPTICAL PATH | July 2020 | May 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 16963286 | Ultrasonic Transducer and Focused Ultrasound Treatment Device | July 2020 | May 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 16962903 | System and Methods for Real Time Raman Spectroscopy for Cancer Detection | July 2020 | June 2024 | Allow | 47 | 4 | 0 | No | No |
| 16958133 | TRANS-ABDOMINAL FETAL PULSE OXIMETRY AND/OR UTERINE TONE DETERMINATION DEVICES AND SYSTEMS WITH ADJUSTABLE COMPONENTS AND METHODS OF USE THEREOF | June 2020 | April 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 16765357 | ULTRASONIC PULMONARY ASSESSMENT | May 2020 | June 2024 | Abandon | 48 | 4 | 0 | Yes | No |
| 16489334 | METHOD OF SCANNING AND ASSESSING LUNG AND VASCULAR HEALTH | August 2019 | June 2024 | Allow | 58 | 4 | 0 | Yes | No |
| 16449759 | WEARABLE ENVIRONMENTAL POLLUTION MONITOR COMPUTER APPARATUS, SYSTEMS, AND RELATED METHODS | June 2019 | October 2023 | Allow | 52 | 7 | 0 | No | No |
| 16466407 | ULTRASONIC SONOTHROMBOLYSIS TREATMENT PLANNING | June 2019 | October 2023 | Allow | 52 | 2 | 0 | No | Yes |
| 16220009 | Handheld Ultrasound Device and Replaceable Tips Therefor | December 2018 | September 2023 | Allow | 57 | 6 | 0 | Yes | No |
| 16214630 | ULTRASONIC DIAGNOSTIC APPARATUS, MEDICAL IMAGE PROCESSING APPARATUS, AND METHOD FOR CALCULATING PLAQUE SCORE | December 2018 | February 2024 | Abandon | 60 | 6 | 0 | No | No |
| 15505635 | GUIDEWIRE FOR OPTICAL SHAPE SENSING | February 2017 | June 2024 | Allow | 60 | 6 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BYKHOVSKI, ALEXEI.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BYKHOVSKI, ALEXEI works in Art Unit 3798 and has examined 25 patent applications in our dataset. With an allowance rate of 80.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner BYKHOVSKI, ALEXEI's allowance rate of 80.0% places them in the 52% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by BYKHOVSKI, ALEXEI receive 3.04 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BYKHOVSKI, ALEXEI is 46 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +22.4% benefit to allowance rate for applications examined by BYKHOVSKI, ALEXEI. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 17.6% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 46.7% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 22% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.